TPST · Tempest Therapeutics, Inc.
$0.92
+0.01 (+1.58%)
At close · Aug 7
Going-concern doubt
— flagged May 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“our need for additional capital to fund our planned programs and operations and to continue to operate as a going concern”View the 10-Q filed May 14, 2026
Market Cap
$13.36M
Shares
14.81M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Stephen Brady | CEO | $1,872,299 |
| Samuel Whiting | Executive Vice President and Chief Medical Officer | $1,062,587 |
| Nicholas Maestas | CFO | $622,095 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Stephen Brady | CEO | $7,007,407 |
| Samuel Whiting | Executive Vice President and Chief Medical Officer | $3,384,949 |
| Nicholas Maestas | CFO | $1,319,038 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Stephen Brady | CEO | $1,514,366 |
| Thomas Dubensky | President and Director | $1,100,586 |
| Samuel Whiting | Executive Vice President and Chief Medical Officer | $833,398 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Louis J. Arcudi III | CEO | $1,632,960 |
| Thomas Dubensky | President and Director | $1,500,167 |
| Julia C. Owens | CEO | $1,339,793 |
| Samuel Whiting | Executive Vice President and Chief Medical Officer | $836,737 |
| Stephen Brady | CEO | $714,721 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Julia C. Owens | CEO | $2,281,928 |
| Louis J. Arcudi III | CEO | $976,240 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Julia C. Owens | CEO | $2,381,882 |
| Louis J. Arcudi III | CFO | $1,003,401 |
| Ryan Zeidan | Chief Development Officer | $849,145 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Julia C. Owens | CEO | $2,424,207 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| William Drake Richey | Class II director | Appointed | 2026-06-04 |
| John David Yee | Class II director | Appointed | 2026-06-04 |
| Ms. Simantov | Board of Directors | Resigned | 2026-05-29 |
| Christine Pellizzari | Board of Directors | Resigned | 2026-05-22 |
| Michael Raab | Board of Directors | Resigned | 2026-05-22 |
| Stephen Brady | Board of Directors | Resigned | 2026-05-22 |
| Geoff Nichol | Class I director | Appointed | 2026-01-28 |
| Geoff Nichol | board of directors of the Company | Resigned | 2025-11-19 |
| Stephen Brady | Chairman of the Company's board of directors | Appointed | 2025-11-19 |
| Matt Angel, Ph.D. | member of the Company's board of directors | Appointed | 2025-11-19 |
| Matt Angel, Ph.D. | Chief Executive Officer and President | Appointed | 2025-11-19 |